Skip to content
Back to explorer
Printable monograph

KIT / PDGFRA inhibitor

Avapritinib

Ayvakit · AVA

KIT / PDGFRA inhibitor · approved 2020 · 5 citations

Aging evidence· through 2021
Thinly sourced3/9 · 3 signals
  • Not met: 5 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 1y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Not met: Current through 2021
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

Potent KIT/PDGFRA inhibitor for D842V-driven GIST and mastocytosis — renal-relevant effects are edema and CNS bleeding/cognitive effects rather than direct nephrotoxicity.

MildMutation-selective KIT/PDGFRA era
Unresectable/metastatic GIST harboring a PDGFRA exon 18 (including D842V) mutationAdvanced systemic mastocytosis (aggressive SM, SM with associated hematologic neoplasm, mast cell leukemia)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Highly protein-bound and not expected to be dialyzable with no established ESKD dosing; no adjustment for mild-moderate impairment, with severe/ESKD not well studied.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
None on the excerpted label
Label: Ayvakit, Oct 2026. FDA label section.
§01

Signature kidney injury

Edema (periorbital/peripheral) is very common, and intracranial hemorrhage and cognitive/CNS effects are labeled toxicities; nausea/diarrhea contribute to volume shifts. Direct nephrotoxicity is not a defined signal and AKI, when it occurs, is secondary (fluid shifts, GI losses, mastocytosis mediator release).Source: Heinrich et al., Lancet Oncol 2020 (NAVIGATOR); DeAngelo et al., Nat Med 2021 (EXPLORER)

Onset & rechallenge

Time to injuryVariable / unpredictable

Edema and cognitive effects occur across treatment, and GI-related prerenal changes track intercurrent toxicity.

Distilled from: “Edema and cognitive effects across treatment; GI-related prerenal changes track intercurrent toxicity.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

  2. Electrolyte DisturbanceSecondaryqualitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

§03

Kidney injury

Mechanism of kidney injury

Avapritinib has no characteristic primary renal lesion. Its renal relevance is indirect: (1) prominent fluid retention/edema reflects vascular permeability changes and can be accompanied by intravascular volume shifts; (2) gastrointestinal toxicity (nausea, diarrhea) causes volume depletion and prerenal azotemia; (3) in mastocytosis, mast-cell mediator-release (flushing, hypotension) can transiently impair renal perfusion. The signature CNS toxicities (intracranial bleeding, cognitive effects) are not renal but dominate the safety profile.

Clinical presentation

Periorbital and peripheral edema, fatigue, nausea/diarrhea, and cognitive effects (memory/attention) or, rarely, intracranial hemorrhage. Renally, a prerenal creatinine rise with GI losses or hypotension; edema may coexist with intravascular depletion.

Management

Treat prerenal AKI with volume repletion and control of GI losses; manage edema with dose modification and supportive measures (avoid over-diuresis that worsens prerenal physiology). Hold/reduce for cognitive effects or any intracranial hemorrhage. Mast-cell mediator events are treated with antihistamines/supportive care; renal effects generally reverse with hemodynamic stabilization.Lesion-level management framework

Risk factors

  • Volume depletion from nausea/diarrhea
  • Pre-existing CKD and concurrent nephrotoxins
  • Mast-cell mediator-release events in mastocytosis
  • Older age and baseline cognitive/vascular vulnerability

Prevention

  • Manage GI toxicity and maintain hydration
  • Manage edema and dose-modify for significant fluid retention
  • Neurologic assessment for cognitive effects/bleeding; dose-reduce per label
  • Mediator-release prophylaxis in mastocytosis as indicated
Anticancer mechanism· how it treats cancer

Oral selective inhibitor of KIT and PDGFRA activation-loop mutants (notably PDGFRA exon 18/D842V and KIT exon 17), conformations resistant to imatinib. It is active in PDGFRA D842V-mutant GIST and advanced systemic mastocytosis.

Note · The renal link is indirect — fluid shifts/edema, GI-loss prerenal physiology, and mastocytosis mediator release rather than a direct renal lesion. The defining toxicities (intracranial bleeding, cognitive effects) are non-renal.
§04

Clinical depth

Renal dose adjustment

No dose adjustment for mild-moderate renal impairment; severe impairment/ESKD not well studied (hepatic CYP3A4 metabolism). Modifications driven by edema, CNS effects and cytopenias.

Dialyzability & ESKD dosing

Highly protein-bound; not expected to be dialyzable. No established ESKD dosing.

Differential diagnosis

Separate prerenal AKI (volume-responsive) from edema with intravascular depletion (avoid aggressive diuresis), and from mediator-release hypotension in mastocytosis. CNS symptoms require distinguishing cognitive toxicity from intracranial hemorrhage by imaging.

Monitoring

  • Volume status, weight and edema assessment
  • Cognitive/neurologic status; prompt imaging for new neurologic symptoms (bleed)
  • Serum creatinine and electrolytes with GI toxicity
  • CBC per schedule

Key trials & series

  • NAVIGATOR (Heinrich, Lancet Oncol 2020) — registrational GIST trial (PDGFRA D842V)
  • EXPLORER/PATHFINDER (DeAngelo, Nat Med 2021; Gotlib, Nat Med 2021) — advanced systemic mastocytosis safety/efficacy

Clinical pearls

  • Edema with concurrent GI losses can mask intravascular volume depletion — assess true volume status before diuresing.
  • Intracranial hemorrhage and cognitive effects are the signature (non-renal) toxicities — they drive dose decisions.
  • In mastocytosis, mediator-release events can transiently impair renal perfusion.
  • There is no characteristic direct avapritinib nephropathy; AKI is secondary.
Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

§05

References

5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

5 references · 2020–2021 · 5 since 2019
402020: 1 citation2021: 4 citations20202021

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkAvapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.Heinrich MC et al. · Lancet Oncol · 2020 · PMID 32615108Registrational GIST trial defining efficacy and the edema/CNS safety profile.
  2. 2.Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.Kang YK et al. · J Clin Oncol · 2021 · PMID 34343033Phase 3 comparative safety dataset.
  3. 3.Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.Gotlib J et al. · Nat Med · 2021 · PMID 34873345Phase 2 PATHFINDER trial in advanced systemic mastocytosis; principal grade >=3 toxicities were cytopenias (neutropenia, thrombocytopenia, anemia).
  4. 4.Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.DeAngelo DJ et al. · Nat Med · 2021 · PMID 34873347Pivotal mastocytosis efficacy/safety confirming the toxicity pattern.
  5. 5.Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.Joseph CP et al. · Oncologist · 2021 · PMID 33301227Practical management of edema, cognitive effects and bleeding.
FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dose adjustment is recommended for patients with mild or moderate renal impairment [creatinine clearance (CLcr) 30 to 89 mL/min estimated by Cockcroft-Gault]. The recommended dose of AYVAKIT has not been established for patients with severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease (CLcr <15 mL/min) [see Clinical Pharmacology (12.3) ] .

Kidney rows of the label's dosage tables

From the Ayvakit label (Oct 2026) · DailyMed

No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 12,654 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
  • Electrolyte DisturbanceNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.
Crystal / Obstructive Nephropathy
ROR 1.5295% CI 1.15–2.01· 50 reports· IC025 0.17
FAERS outcomes & reporting trend· 3% of reports w/ death · 9.6% w/ hospitalization
3%

Reported with a death outcome

380 of 12,654 reports

9.6%

Reported with hospitalization

1,213 of 12,654 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 2 reports
  • 2019: 0 reports
  • 2020: 498 reports
  • 2021: 1,387 reports
  • 2022: 2,358 reports
  • 2023: 1,775 reports
  • 2024: 2,320 reports
  • 2025: 2,496 reports
  • 2026: 1,818 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 12,654 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.0995% CI 0.05–0.17· 11 AKI reports· IC025 −4.35·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.
General / constitutional
Fatigue1,855Asthenia497Peripheral Swelling483Pain448Malaise360
Gastrointestinal
Nausea1,306Diarrhoea1,062Vomiting549Abdominal Pain Upper324
Nervous system
Headache607Dizziness571
Skin
Rash486Pruritus341
Blood & lymphatic
Platelet Count Decreased470
Metabolic & electrolyte
Decreased Appetite440
Psychiatric
Insomnia419
Eye
Eye Swelling407
Musculoskeletal
Arthralgia327
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Avapritinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Quizartinib

Vanflyta · FLT3 inhibitor

Profile

2023 AML FLT3 inhibitor; tumor lysis and QT.

PRELYTE
Mild#1 · 100% phenotype match

Imetelstat

Rytelo · Telomerase inhibitor

Profile

2024 MDS agent; tumor lysis risk.

PRELYTE
Mild#2 · 89% phenotype match

Zanidatamab

Ziihera · HER2 bispecific antibody

Profile

2024 biliary-tract HER2 bispecific; renal data emerging.

PRELYTE
Mild#3 · 89% phenotype match

Zenocutuzumab

Bizengri · HER2×HER3 bispecific antibody

Profile

2024 NRG1-fusion bispecific; mostly grade 1-2 AEs — at most diarrhea-related prerenal risk, no CRS/TLS mechanism.

PRELYTE
Mild#4 · 89% phenotype match

Mirdametinib

Gomekli · MEK inhibitor

Profile

2025 NF1 MEK inhibitor; creatinine rise and edema.

PRELYTE
Mild#5 · 89% phenotype match

Midostaurin

Rydapt · FLT3 / multikinase inhibitor

Profile

Tumor lysis, edema and QT in AML/mastocytosis.

PRELYTE
Mild#6 · 88% phenotype match
Compare Avapritinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Other kinase inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1PexidartinibMild
  2. 1RipretinibMild
  3. 3Avapritinib· this agentMild
  4. 3FedratinibMild
  5. 3MidostaurinMild
  6. 3MomelotinibMild
  7. 3QuizartinibMild
  8. 3VimseltinibMild
  9. 9PralsetinibMild
  10. 9RuxolitinibMild
  11. 11PacritinibModerate
  12. 12SelpercatinibModerate
  13. 13GilteritinibFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.